LEADER 01627nam  2200421 a 450 
001 9910700937003321
005 20110915070449.0
035   $a(CKB)5470000002413659
035   $a(OCoLC)752431958
035   $a(EXLCZ)995470000002413659
100   $a20110915d2011      ua             0
101 0 $aeng
135   $aurmn|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aEnd-stage renal disease$b[electronic resource] $eCMS should assess adequacy of payment when certain oral drugs are included and ensure availability of quality monitoring data : report to congressional committees
210  1$a[Washington, D.C.] :$cU.S. Govt. Accountability Office,$d[2011]
215   $a1 online resource (ii, 39 pages) $cillustrations
300   $aTitle from PDF title screen (viewed Sept. 12, 2011).
300   $a"March 2011."
300   $a"GAO-11-365."
320   $aIncludes bibliographical references.
517   $aEnd-stage renal disease 
606   $aOral medication$xEconomic aspects$zUnited States
606   $aHemodialysis$xPatients$xEconomic aspects
606   $aHemodialysis$xPatients$xMedical care$xGovernment policy$zUnited States
606   $aMedicare$xEconomic aspects
615  0$aOral medication$xEconomic aspects
615  0$aHemodialysis$xPatients$xEconomic aspects.
615  0$aHemodialysis$xPatients$xMedical care$xGovernment policy
615  0$aMedicare$xEconomic aspects.
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910700937003321
996   $aEnd-stage renal disease$93440710
997   $aUNINA